Our findings suggest that patients with concurrent SMAD4 and TP53 mutation represent a distinct prognostic subgroup that may benefit from further translational study, and this should be considered as a stratification biomarker in future prospective trials in metastatic colorectal cancer. Here, SMAD4 is linked to metastatic colorectal cancer.